Pharma: Clinic Roundup
Monday, July 29, 2013
Takeda Pharmaceutical Co. Ltd., of Osaka, Japan, unblinded the ELM-PC 5 Phase III study (C21005) of orteronel plus prednisone compared to placebo plus prednisone in patients with metastatic, castration-resistant prostate cancer that had progressed during or following chemotherapy based on the recommendation of the independent data monitoring committee.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.